FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL
=	

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* WOLLAEGER TIMOTHY					2. Issuer Name and Ticker or Trading Symbol CHIMERIX INC [CMRX]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner						
.ast) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 09/12/2014									Х	Officer (give title below)		Othe		(specify	
2505 MERIDIAN PARKWAY, SUITE 340					If Amendment, Date of Original Filed (Month/Day/Year)										vidual o	r Joint/Grou	ıp Filing	(Check	Applicable	
(Street)															Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
DURHAM NC 27713																				
Sity) (State) (Zip)																				
	Tab			_			_		_						Owne	ed				
Da			Date		Execution Date,		c		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			d (A) o r. 3, 4 a	4 and Securitie Beneficia		ies cially			7. Nature of Indirect Beneficial Ownership		
								Code		Amount		(A) or (D)	Pric	Reported		ed ction(s)	, ,		(Instr. 4)	
ck		09	/12/201	4				J ⁽¹⁾		164,60	00	D	\$	0	3,70	66,100		т г	See Footnote ⁽²⁾	
ck		09	/12/201	4				J ⁽³⁾		40,30	0	D	\$	0	3,72	25,800			See Footnote ⁽²⁾	
ck		09	/12/201	4				J ⁽⁴⁾		81,20	0	D	\$	0	3,64	44,600			See Footnote ⁽²⁾	
ck		09	/12/201	4				J ⁽⁵⁾		133,90	00	D	\$	0	3,5	10,700		т і	See Footnote ⁽²⁾	
ck		09	/12/201	4				J ⁽⁶⁾		199,30	00	D	\$	0	3,3	11,400			See Footnote ⁽²⁾	
Common Stock			09/12/2014				J()(3)(4)(5)(6)		158		A	\$0		8,891		I		See Footnote ⁽⁷⁾	
Common Stock			09/12/2014					J ⁽⁸⁾		8,733	3	D	\$	0	158				See Footnote ⁽⁷⁾	
Common Stock			09/12/2014					_J (4)(5)(6)(8)		8,601		A	\$	0	8,601				See Footnote ⁽⁹⁾	
	Ta														wned					
nversion	se (Month/Day/Year)	3A. Deeme Execution if any	Execution Date, if any		action	5. Number of Derivative Securities Acquired (A) or Disposed of (D)		6. Date Exerci Expiration Date (Month/Day/Ye		able and	7. T Ame Sec Und Der Sec	7. Title and Amount of Securities Underlying Derivative		8. F Der Sec	ivative curity	derivative Securities Beneficiall Owned Following Reported	y O F D o (!	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisabl		Expiration Date	Title	or Nu of								
	(First (First NC) (First NC) (State NC) (Sta	(First) (First) (RIX, INC. DIAN PARKWAY, SUIT NC (State) Tab rity (Instr. 3) Ck Ck Ck Ck Ck Ck Ck Ck Ck C	(First) (Middle) RIX, INC. DIAN PARKWAY, SUITE 340 NC 27713 (State) (Zip) Table I - Nor rity (Instr. 3) 2. Tr. Date (Mor Ck 09 Ck	(First) (Middle) RIX, INC. PIAN PARKWAY, SUITE 340 NC 27713 (State) (Zip) Table I - Non-Deriverity (Instr. 3) 2. Transaction Date (Month/Day/Year) Ck 09/12/201-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-	Carrow C	CHIME	GER TIMOTHY (First) (Middle) RIX, INC. DIAN PARKWAY, SUITE 340 Table I - Non-Derivative Securities rity (Instr. 3) Table I - Non-Derivative Securities rity (Instr. 3) Z. Transaction Date (Month/Day/Year) Rix (Month/Day/Year) Rix (Month/Day/Year) A. Deemed Execution Date, if any (Month/Day/Year) Rix (Month/Day/Year) Rix (Month/Day/Year) A. If Amendment, In the A	GER TIMOTHY (First) (Middle) RIX, INC. DIAN PARKWAY, SUITE 340 Table I - Non-Derivative Securities Active (Month/Day/Year) Table II - Derivative Securities Active (e.g., puts, calls, warrants. Table II - Derivative Securities Acqueed (A) or Date (Month/Day/Year) Table II - Derivative Securities Acqueed (A) or Date (A) or Date (A) or Date (A) or Date (A) or Derivative (A) or Derivativ	CHIMERIX INC CMR.	CHIMERIX INC CMRX CMRX Sult CMRX Sult CMRX Sult CMRX Sult CMRX CMRX	CHIMERIX INC CMRX	CHIMERIX INC CMRX	CHIMERIX INC CMRX CHIMERIX INC CMRX CHIMERIX INC CMRX CHIMERIX INC CMRX CMR	CHIMERIX INC CMRX CM	CHIMERIX INC CMRX Check CMRX Check CMRX Check CMRX CMR	Chimerix Inc. Chimerix Inc. Community Check all app X Direct	Chick all applicable Chick all applicable	CHIMERIX INC CMRX Check at Injection Companies Companies	CHIMERIXINC CMRX Survival CMRX CMRX Survival Survival	

- $1.\ Pro\ rata\ distribution\ for\ no\ consideration\ by\ Sanderling\ Venture\ Partners\ V,\ L.P.\ to\ its\ partners.$
- 3. Pro rata distribution for no consideration by Sanderling V Biomedical, L.P. to its partners.
- 4. Pro rata distribution for no consideration by Sanderling V Biomedical Co-Investment Fund, L.P. to its partners.
- 5. Pro rata distribution for no consideration by Sanderling Venture Partners V Co-Investment Fund, L.P. to its partners.
- 6. Pro rata distribution for no consideration by Sanderling Venture Partners VI Co-Investment Fund, L.P. to its partners.
- 7. The shares are held of record by Kingsbury Associates, LP.
- 8. Pro rata distribution for no consideration by Kingsbury Associates, LP to its partners.
- 9. The shares are held of record by the Timothy J & Cynthia K Wollaeger Trust.

/s/ Timothy J. Wollaeger

09/16/2014

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Following the pro-rata distribution reported herein, the shares of Common Stock are held as follows: 829,046 shares of common stock held by Sanderling Venture Partners V, L.P., 233,134 shares of common stock held by Sanderling V Biomedical, L.P., 155,143 shares of common stock held by Sanderling V Limited Partnership, 138,046 shares of common stock held by Sanderling V Beteiligungs GmbH & Co. KG, 199,853 shares of common stock held by Sanderling V Biomedical Co-Investment Fund, L.P., 329,682 shares of common stock held by Sanderling V Shares), 498,046 shares of common stock held by Sanderling V Shares of common stock held by Sanderling V Shares, 498,046 shares of common stock held by Sanderling VI Beteiligungs GmbH & Co. KG, 18,384 shares of common stock held by Sanderling VI Limited Partnership (collectively, the Sanderling VI Shares), 3,446 shares of common stock held by Middleton-McNeil Retirement Trust. Timothy J. Wollaeger, one of the Issuer's directors, Fred A. Middleton, Robert G. McNeil and Timothy C. Mills share voting and investment power with respect to the Sanderling VI Shares. Fred A. Middleton and Robert G. McNeil share voting and investment power with respect to the Sanderling VI Shares. Fred A. Middleton and Robert G. McNeil share voting and investment power with respect to the Sanderling VI Shares. Fred A. Middleton and Robert G. McNeil share voting and investment power with respect to the Shares held by the Middleton-McNeil Retirement Trust. Each of these individuals disclaims beneficial ownership of such securities, except to the extent of his or her pecuniary interest therein.